FGL-L · FGLL Peptide
FGL(L) is a synthetic peptide derived from the neural cell adhesion molecule (NCAM) that mimics the interaction between NCAM and fibroblast growth factor receptor (FGFR). NCAM-FGFR signaling is critical for synaptic plasticity, neurite outgrowth, and neural circuit formation. FGL(L) is the L-amino acid version of the FGL peptide, designed to enhance neural plasticity and cognitive function through FGFR activation without requiring cell-cell contact.
Any time of day. No fasting required. NCAM mimetic for neuroprotection.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
FGL(L) binds to and activates fibroblast growth factor receptor (FGFR), mimicking the signaling that normally occurs when NCAM molecules on adjacent neurons interact. This activates downstream pathways including MAPK/ERK and PI3K/Akt, promoting neurite outgrowth, synaptic strengthening, long-term potentiation (LTP), and neural circuit formation. By delivering this signal as a soluble peptide, FGL(L) can enhance plasticity without requiring direct cell-cell contact.
Days 1-14: Minimal changes.
Weeks 2-6: Plasticity improvements may emerge.
Weeks 6+: Cumulative effects.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
FGL activated FGFR1, enhanced presynaptic function, and promoted synapse formation.
In primary cultures of hippocampal neurons, FGL enhanced the presynaptic function through activation of FGFR1 and promoted synapse formation.
Evidence scope. Preclinical neuron culture; not SubQ human evidence.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 500 mcg-1 mg SubQ. Human data used single intranasal 25-200 mg doses and was rejected for mismatch.
Repeated-SubQ safety. Intranasal single-dose tolerability cannot establish it.
NCAM mimetic
Confirmed mechanism. Soluble peptide that replicates cell-cell adhesion signaling for neural plasticity.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
SubQ
Downstream FGFR signaling effects may persist longer
Enzymatic degradation and renal clearance
Storage. Standard BAC water 2-8C. 28 days.
Research compound only. Not FDA-approved.
Put it to work
Open FGL(L) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open FGL(L) in the app →Go deeper
The complete FGL(L) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.